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by Norman Breslow*
Methods ofstatistical analysisofcensored survival times are briefly-reviewed and illustrated by applica-
tion toclinical trials data. These include estimation ofthe survival curve, nonparametric tests tocompare
severalsurvivalcurves, testsfortrend, andregressionanalysis. Extensionsofthemethodology aremadefor
application to epidemiologic case-control studies. These are used to estimate relative risks for leukemia
asociated with radiation exposures. A final section provides some annotated references to the recent
literature.
Introduction
Censored survival data arise in a wide variety of
statistical investigations. In clinical trials one mea-
sures duration of response from start of treatment
until relapse or death due to disease. Observations
on response time are censoredforthose subjects still
in remission at the study's end, as they are for pa-
tients lost tofollowup during the course ofthe study.
Animal carcinogenesis studies, such as used by the
United States Food and Drug Administration to de-
termine the safety offood additives, provide another
example. Here the endpoint is the age atdiagnosis of
a particular kind of cancer, censorship being im-
posed by death due to other causes, natural or artifi-
cial. In tests of the reliability of airplane compo-
nents, failure times are measured from the start of
testing until failure of the component, with censor-
ship imposed by the failure of other components or
the necessity of analyzing the data before all items
have failed.
Figure 1 illustrates the resultsforthecontrol group
in aclinical trial designed to investigate the effects of
combined chemotherapy as an adjunct to surgery
and radiation in the treatment of childhood rhab-
domyosarcoma (1). The endpoint for analysis was
the reappearance of tumor, whether at the site of
original treatment or through distant metastasis.
Children who remained disease-free at the time the
*Department ofBiostatistics SC-32, University ofWashington,
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data were analyzed had censored observations. In
addition to the control arm IA, there were two
groups of children who received the drugs actino-
mycin-D (AMD) and vincristine (VCR): group IB
patients were concurrently randomized with the
controls, both these groups having apparently had
their tumors completely resected; group IIA con-
sisted ofpatients with microscopic residual disease
at the margin of surgical resection.
Interim data from all three arms are presented in
Table 1. Notethatthecensored observationsforarm
IA, those in the column labeled "disease-free", are
smallerinthe tablethanthey are in thefigure. This is
because thefigure was drawnfrom datacomputed at
alater point in time, when additional follow-up was
available for patients who had not already died.
Analysis of such data has several goals. For each
ofthe comparison groups one wants an estimate of
thesurvivalcurve,theprobabilityofsurvivingtunits
of time. Statistical tests are required to determine
whether the observed differences between the
curves are real, or are simply chance effects. Ifreal,
amethod ofquantifying the nature ofthe differences
is desirable. Finally there may be available con-
comitant observations, including continuous mea-
surements such as age at diagnosis, whosejoint ef-
fects on survival are important to determine.
Estimation of Survival Curves
When analyzing several groups of survival times
the first step is to form a series of 2 x r tables as
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FIGURE 1. Course of patients following surgery for rhabdomyosarcoma in Part IA, control group.
shown in Table 2. One table is formed for each of the
Kdistincttimesti <t2 < . .. < tK atwhich deaths (or
failures or relapses) occur. The column totals nik
Table 1. Interim clinical trial data: time from start oftreatment to
relapse or last observation for three treatment groups.
Time, months
Tumor completely resected Microscopic residual
Surg + x-ray Surg + x-ray
Surg + x-ray + AMD + VCR + AMD + VCR
(IA) (IB) (IIA)
Disease- Disease- Disease-
Relapsed free Relapsed free Relapsed free
2 12 9 12 37 25
3 15 16 19 28
9 18 19 20 29
10 24 20 38
10 36 24 42
15 40 24 45
16 45 30 47
30 31 48
34 50
42 52
44
53
59
62
refer to the total number of subjects in the ijh group
who remain "at risk", i.e., alive and under observa-
tion,just prior to time tk. The tabular entriesdik and
Sik denote the numbers of those who die at tk, and
survive tk, respectively. Table 3 illustrates the cal-
culation of the first three such tables for the data in
Table 1. Here r = 3 and ti = 2, t2 = 3, and t3 = 9
months. Note thatthetables forincreasing tkreferto
a constantly diminishing population "at risk" as
additional subjects die or are withdrawn (censored)
from further observation.
Kaplan and Meier (2) derived the maximum likeli-
hood nonparametric estimate of the survival curve
based on censored data. This may be calculated re-
cursively, starting from P(to) = 1, and by using the
formula (1):
P(Ok) = P(tk-1) (Sklnk) (1)
Table 2. Formation of 2 X r contingency tables comparing death
rates among r treatment groups at each distinct time of death.
Patients followed to time tk for various treatment groups
1 2 - r Totals
Deaths (at tk) dlk d2k drk Dk
Survivors Sik 52k Srk Sk
Total "at risk" nlk n2k nrk Nk
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t, months IA IB IIA Total
2 Relapsed 1 0 0 1
Disease-free 14 17 11 42
"At risk" 15 17 11 43
Expectations: 0.349 0.395 0.256 1.000
3 Relapsed 1 0 0 1
Disease-free 13 17 11 41
"At risk" 14 17 11 42
Expectations: 0.333 0.405 0.262 1.000
9 Relapsed I I 0 2
Disease-free 12 16 11 39
"At risk" 13 17 11 41
Expectations: 0.634 0.829 0.537 2.000
for k = 1, 2, . . ., K. (The group index i has been
suppressed for clarity.) In other words, the proba-
bility of surviving past tk is estimated as the proba-
bility of surviving past tk-l times the conditional
probability of surviving past tk given survival to tk.
Because ofthis multiplicative structure, Kaplan and
Meierrefertotheirestimate astheproductlimit(PL)
estimate. Incasethere is nocensorshipinthedata, it
reduces to the familiar empirical distribution func-
tion.
Table 4 shows the calculation of the relapse-free
survival curve from the interim data in Table 1 for
treatment group IA. The corresponding curves cal-
culated from final study data for all three treatment
curves are shown in Figure 2. Numbers above each
curve at annual intervals in this figure refer to num-
bers ofpatients still at risk in each group. These are
an important means ofjudging the stability of the
estimates, which can in fact be quite unstable in the
"tail" ofthe survivaldistribution wherefewsubjects
remain at risk.
The variance ofthe PL estimate may also be cal-
Table 4. Estimation of survival curve for group IA.
Time, Number Number Conditional Survival
months at risk surviving probability probability
tk nlk Slk NO POO
2 15 14 0.933 0.933
3 14 13 0.929 0.866
9 13 12 0.923 0.799
10 12 10 0.833 0.666
15 9 8 0.888 0.592
16 7 6 0.857 0.507
30 4 3 0.750 0.381
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FIGURE 2. Duration of the disease-free interval in patients from
Part IA (control), IB (treated), and IIA (microscopic residual,
treated). Shown above each curve at 24 and 48 months are the
numbers ofpatients known to be disease free after those time
periods.
culatedrecursively, startingfrom V{P (to)} = 0. One
uses the formula (2)
V{P (tk)}
V{P (tk-1)} (5 k/l k) + {P (tk)} [dkl(nkSk)] (2)
with the understanding that it is appliedse;quentially
to tied observations. In large samples, P(t) is ap-
proximatelynormallydistributedwithmeanequal to
the true survival function P(t) and a variance esti-
mated as shown above (2, 3). Note that neitherP (t)
nor V{P (t)} will change after the last uncensored
response time ineach group, even though additional
subjectscontinuetobewithdrawnfromobservation.
In this region the estimated variance often does not
accurately reflect the true variability in the survival
curve, which will be substantial unless large num-
bers of subjects remain on study.
Comparison of Survival Curves
A simple but powerful non-parametric test for the
comparison ofr survival curves with censored data
may also be calculated from the basic data shown in
Table2.Thistestexploitsthefactthat, underthe null
hypothesis ofno difference in the underlying survi-
val distributions and conditional upon fixed values
forthe marginal totals in each 2 x r table, the vector
dk = (dlk, ..., drk)' ofobserved deaths at tk has an
r-dimensional hypergeometric distribution. Con-
sequently the null expectation of the number of
deaths in group i at tk is
eik = E(dik) = nik (Dk,Nk) (3)
i.e., the number at risk in the i-th group times the
death rate for all r groups combined (see Table 3 for
October 1979 183an illustration of this calculation). The covariance
matrixVkofdk has, underthe null hypothesis, an(i,j)
component equal to
IlVkIIu
=
nfik(Nk - nfik) D, kN =J
N2k (Nk - 1)
niknjkDkSk
N2k (Nk-1)
(4)
7
,
The main idea behind the test is to sum up the
statistics calulated from each of the K tables into a
vector 0 = Ykdk of observed numbers of deaths in
each group, a vector E = :kek ofexpected numbers
of deaths, and a summary covariance matrix V =
IkVk. Since the 2 x r tables refer tooverlapping sets
of subjects they are not, strictly speaking, statisti-
cally independent. Nevertheless Cox (4) has shown
that V is an appropriate large sample covariance
matrix for O-E. Since YOi = ;Ei, i.e. the totals of
observedandexpected deaths in allrgroups agree, V
is singular. However, defining 0* and E* to be the
first r - 1 components of0 and E, and V* to be the
(r - 1) x (r - 1) upper left hand corner ofV, a test
statistic fortestingequality ofther survival curves is
obtained as
Ti = (0* - E*)'V*-l (0* - E*) (5)
This is approximately distributed as chi-square on
r - 1 degrees offreedom under the null hypothesis.
The test Ti was first proposed for survival databy
Mantel (5). Cox (6) later derived it from likelihood
theory under the proportional hazards (PH) model,
inwhichthe instantaneous death ratesinthergroups
are assumed to be in constant ratio throughout the
follow-up period (see below). Peto and Peto (7) ar-
guedthatitwasanasymptotically efficienttestunder
Cox's model and named it the "log rank" test.
A conservative approximation to Ti which re-
quires no matrix inversion is given by the familiar
chi-square formula
T2 = E (O - E )2/E,
i=, (6)
While T2 ' Ti, in fact the two statistics will be quite
close, provided that there are few ties among the
uncensored survival times (i.e., most of the Dk in
Table 2 areunity) and thatthe patterns ofcensorship
operating in the r groups are not grossly different (8,
9). Note that the ½ continuity correction should not
be used with survival data.
Table 5 illustrates the manner of presentation of
the summary and test statistics. Note the calculation
ofthe ratio O/E ofobserved to expected numbers of
Table 5. Summary statistics for interim clinical trial data.
Treatment group
IA IB IIA
No. of patients (N) 15 17 11
Relapses observed (0) 8 3 1
Relapses expected (E) 3.11 4.99 3.90
OIE 2.57 0.60 0.26
W scores -179 68 111
Covariance matrix V
2.22
-1.27 2.86
-0.94 -1.59 2.53
Covariance matrix V,,
2954
-1748 3572
-1206 -1824 3030
aTest statistics:
Ti = 11.10,2 df,p = 0.004
T2 = 10.77, 2 df, p = 0.005
T3 = 11.41, 2 df, p = 0.003
T4 = 11.20,2 df,p = 0.004
deaths in each treatment group. These are very use-
fulasmeasures oftreatmenteffect, sincetheirratios,
e.g., OiIEl . 021E2, approximate the ratios ofdeath
rates in the respective treatment groups (10).
Alternate Weighting Schemes
The summary statistics0 - Eweightthe observed
differencesdk - ek in each table in amannerwhich is
appropriate to the PH model already mentioned.
However this is not the only possible weighting
scheme. Multiplyingtheobserved differences byNk,
the total number of subjects in the k-th table, and
thensumming, gives more weightto the earliertimes
tk when larger numbers are at risk. This leads to the
scores
K
Wj = I {Nkdik- nikDk}
k = 1
covariance matrix
K
VW = I Nk2Vk
k = 1
and test statistic
T3 = W*'Vw*-lW*
(7)
(8)
(9)
where asterisks (*) denote the corresponding r - 1
dimensional quantities. A conservative approxima-
tion to T3 not requiring matrix inversion is
Environmental Health Perspectives 184T4 = I W?2/G1
i=1
with
K
Gi= E {NkDkSkniklNk-l}
k = 1
(10)
(11)
The scores Wi may also be obtained from a pair-
wise comparison of the observations in the i-th
treatment group with those in the remaining r - 1
groups. Each such pair is assigned the value +I (or
-1) according as the true survival time for the first
pair member is known to be smaller than (or larger
than) thatforthe second member. Ties orindetermi-
nate comparisons due to censorship are assigned 0
values. Gehan (11) suggested the use ofsuch scores
for the comparison of two samples (r = 2). In this
case T4 reduces to the familiar Wilcoxon rank sum
test in the absence of ties and censorship. Breslow
(12) extended this work to r > 2 samples, proposing
the covariance matrix Vw and the statistic T3. These
latterstatistics, like Vand Ti, are validfor situations
where the patterns of censorship operative in the r
treatment groups are unequal, as in animal car-
cinogenesis studies where there is differential toxic
mortality. The conservative approximation T4, like
T2, is strictly valid only where there is equality of
censorship.
In practice, the tests Ti and T3 often yield rather
similar numerical values (see Table 5). However,
this is not always true, and some comment on the
proper interpretation when only one statistic is sig-
nificant is in order. Since T3 weights early values
moreheavily, itmayachieve significancewhenthere
is an early separation between the survival curves
which later come together or even cross over. Ti
gives more weight to the later appearing deaths. A
large discrepancy between Ti and T3 generally indi-
cates an interaction between treatment and time on
the instantaneous death rates, which is worthy of
investigation in its own right.
Testing for Trend
Often the r comparison groups correspond to r
levelsxl <X2 < . . .Xrofaquantitative variable such
as dose. Global chi-square tests such as Ti through
T4lack statistical powerin such situations since they
take no account of the natural order of the groups.
Oneneeds asingledegreeoffreedomtestfortrend in
survival with increasing dose.
Fortunately such a test is readily calculated from
the summary statistics already athand. Inthecase of
the log rank analysis
(12) T5 = {x' (O-EW
x'Vx
is a single degree offreedom chi-square for a linear
trend ofO-E withx. Tarone (13) has suggested using
T6 = Ti - T5 as a chi-square on r-2 degrees offree-
domfordeviations from linearity. An approximation
to T5 which only requires calculation ofthe 0 and E
vectors is given by
T7 = {Xxj (Oi - E)J2
YX2 E - (XxiE)2IYEi
Similarly, when using the W scores,
T8={x'W}2 T8 = v
X'V,,x
(13)
(14)
providesatestforlineartrend andT9 = T3 - T7 atest
for deviations from linearity.
To illustrate these calculations by using the sum-
mary datainTable 5, make the fictitious assumption
that the three treatment groups IA, IB, and IIA cor-
respond to dose levels xi = 0, X2 = 1, X3 = 2. The
statistics for trend are T5 = 9.17 (p = 0.002), T7 =
8.72 (p = 0.003), and T8 = 10.02 (p = 0.002). The
deviation chi squares are T6 = 1.93 (NS) and Ts =
1.39 (NS). Hence, this would be a case where the
already significant differences are largely explained
on the basis of an apparent linear trend in survival
with increasing dose.
Adjustment by Stratification
When the r comparison groups differ with respect
to factors which influence survival, an analysis
whichcorrectsfortheirpossible confoundingeffects
is needed. This may be carried out very simply by
dividingthe population into stratawhich are more or
less homogeneous internally with respect to the
confounding factors. (Ofcourse the number ofcon-
founders which may be accommodated simultane-
ously inthisfashion is limited, since ifstratabecome
very large in number and small in size a substantial
loss of comparative information may result.) Sepa-
rate survival analyses are performed within each
stratum by calculating the summary statistics 0, E,
andVdefinedearlier. These are cumulatedby simple
addition over strata and used to calculate adjusted
test statistics Ti, T2, T5, T6 and T7, in which the
cumulated summary statistics replace the stratum
specific ones. Likewise adjusted versions ofT3, T8,
and Ts use the cumulated W and Vw statistics.
Such a stratified analysis was used for a trial of
maintenance chemotherapy for children with acute
October 1979 185lymphocytic leukemia (14). Forthis disease it is well
known that the diagnostic white blood count (WBC)
is an important prognostic factor. The treatment
group, consisting of 152 children who received ac-
tinomycin (AMD) in addition to standard mainte-
nance drugs, had a median WBC of 10,067; whereas
thecontrol group, consisting of 116children who did
not receive AMD, had a median WBC of 14,280. An
analysis ignoring this difference in WBC compared
the observed number of relapses in the treated and
control groups, O1 = 100 and 02 = 81, with expected
numbers ofEl = 113.00 andE2 = 68.00. This yielded
an(unadjusted) chi-square ofT2 = 3.98, which isjust
on the borderline of 5% statistical significance.
In order to determine whether the apparent effec-
tiveness of AMD was due, at least in part, to the
generally lower WBC's among treated patients, the
entire sample of268 children was divided into three
strata as shown in Table 6. A separate calculation of
the observed and expected numbers ofrelapses was
made within each stratum, so the totals of O's and
E's taken across each row of Table 6 agree. The
adjusted expected numbers, El = 110.96 and E2 =
70.04, are now closer to the observed numbers and
give an adjusted chi-square of T2 = 2.80, which is no
longer statistically significant.
The estimated ratio of relapse rates in the treated
vs. control group is 100/113.0 . 81/68.0 = 0.74.
When adjusted for WBC in three strata, it is 100/
110.96 . 81/70.04 = 0.78, again indicating less of a
difference between treatment and control group.
Regression Analysis of Survival
Data
If the number of confounding variables is large,
stratification breaks down since there will be many
strata withjust one or a few subjects. It may also be
ofinterest to quantify the relationship between sur-
vival and several discrete or continuous and con-
Table 6. Stratified analysis of additive maintenance therapy for
childhood leukemia according to diagnostic white blood count.
Treated patientsa Controlsa
White blood
count(stratum) N 0 E N 0 E
0-4,999 51 25 27.08 36 18 15.92
5,000-19,999 58 38 44.64 37 18 21.16
20,000 + 43 37 39.04 43 35 32.%
Totals 152 100 110.96 116 81 70.04
aN = numberofpatients; 0 = observed numbers ofrelapses;E
= expected numbers of relapses.
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comitant variables. This situation calls for a regres-
sion approach.
The usual regression model specifies that the
survival times, or some transform such as their
logarithm, are equal to a linear combination of the
concomitant variables plus a random error term.
Unfortunately, to generalize such models for use
with censored data is awkward and computationally
involved. Thus considerable interest was arousedby
Cox (6) when he proposed a model formulated in
terms of the effect of the regression variables on
instantaneous death rates rather than on times of
deathper se. This model turned out to be quite tract-
able computationally and, as an added benefit,
avoided any parametric assumptions aboutthe shape
of the underlying survival curve.
Cox's model is defined in terms of the time t
specific death rate or hazard function X(tlz) for an
individual having ap-vector ofcovariates z. Specifi-
cally he assumes X(tlz) = exp(,f'z)Xo(t), where ,3 is an
unknownp-vector of parameters (regression coeffi-
cients), while Xo(t) is the unknown hazard or death
ratefunctionfor anindividualwith astandard(z = 0)
set of convariates. A consequence of this model is
that the ratio ofhazard functions for two individuals
with different sets of covariates,
X(tlzi)
-= exp {,B' (zl - Z2)}
X(tIz2)
(15)
does not depend on time. Thus it is called the pro-
portional hazards (PH) model.
Several authors (4, 6, 10, 15-17) have developed
the likelihood analysis of the PH model from rather
distinct points of view. Providing that there are no
ties in the uncensored data, all derive for the ln-
likelihood function of the expression
K
L(/3) = E {f3'Z, - In X exp (/3'zj)}
k = I j R(t)
(16)
Table 7. Illustration of fitting of proportional hazards regression
model to data on 268 children with acute leukemia.
Regression coefficients
No. of Ln-
vars Likelihood log(WBC) Age Age2 RX (0/1)
0 -900.84
1 -881.57 0.783 -
(6.367)a
3 -877.99 0.737 -0.186 0.0145
(5.876) (-2.290) (2.621)
4 -876.95 0.721 -0.189 0.0148 -0.220
(5.709) (-2.316) (2.647) (-1.452)
aStandardized regression coefficients in parentheses.
Environmental Health Perspectiveswhere R(tk) is the risk set of subjects still alive and
under observationjust prior to tk; Zk is the covariate
vectorforthe individual who dies attk; and the outer
summation is over all K true (uncensored) times of
death. Different likelihoods arise in the case ofties.
Taking the vector offirst partial derivatives ofL,
settingequal to0 and solving the resulting nonlinear
equations yields a maximum likelihood estimate 3
for the regression coefficients. A covariance matrix
for this estimate is obtained in the usual fashion by
inversion of the negative of the matrix of second
partials of L. The integral
I.t
Ao(t) = J Xo(u)du (17)
defines the cumulative hazard function for the stan-
dard covariate set. Once f3 is obtained this may be
estimated by
Ao(t) = z (i exp {f'zj})-1 (18)
tk!S t J f R(tkd
where the outer summation is again over true survi-
valtimestkless than orequal tot. The corresponding
estimate of the survival function
Po(t) = exp { -Ao (t)} (19)
is
Po(t)= I 11- 1
tkS t I exp (,3z,)
je R(tk) (20)
Notice that when ,3 = 0 this reduces to the PL esti-
mateofKaplanand Meier, calculatedfromtheentire
set ofobservations considered as one homogeneous
sample.
Table 7 illustrates the computer fitting of the PH
model to the data on 268 leukemic children. Four
regression variables were considered: zi = log
(WBC), Z2 = age at diagnosis (years), Z3 = Z2, andZ4
= 1 or 0, according as the patient was treated with
AMD or was a control. These four variables were
entered into the regression equation sequentially in
order to demonstrate their effects on remission du-
rationafteradjustmentfortheprecedingvariables. A
quadratic term inthe age variable was required: chil-
dreninthe mid ranges from 2 to 6 years have abetter
prognosis than at either extreme. The multiplicative
effectoftreatment on the relapse rate isgivenby exp
(J34) = exp (- 0.220) = 0.80, which is quite compara-
ble with the approximate value 0.78 obtained from
the simpler stratified analysis. The likelihood ratio
testfortreatmenteffectiveness yields achi-square of
2(-876.95 + 877.99) = 2.09; squaring the standard-
ized regression coefficient gives a similar value
(_1.45)2 = 2.11. These are both even smaller than
the value of2.80 obtained after adjustment forWBC
inthree strata, so thatthe regression approach has in
this case led to an even greater reduction in the
statistical significance ofthe treatment comparison.
As a means ofproviding a graphical display ofthe
fit of the model, the regression coefficients were
used to calculate a prognostic score for each child
using the formula
S = Z1f31 + Z2f32 + Z3133 + Z4/34 (21)
Each of the covariates z was first normalized by
subtracting offthe mean, so that a scoreS = 0 repre-
sents a "typical" patient. The scores were then used
to divide the sample into four groups within each of
which PL estimates of the remission duration were
calculated. These are plotted in Figure 3 together
with predicted remission duration curves, estimated
fromthe model, forspecified valuesofS. Notice that
the predicted curves lie further apart than do the
"observed" curves for later days, while the reverse
is true for earlier days. This behavior indicates a
certain lack of fit of the model, namely that the
baseline covariates have more of an effect on early
rates of relapse than they do on later ones. The fit
could be improved by use of time-dependent
covariates z(t) as discussed by Cox (6).
The PH Model in Epidemiology:
Applications to RERF Data
The methodology of survival analysis, especially
the PH model developed in the last section, is also
useful with epidemiologic studies of risk factors for
chronic disease. In this context t often represents
age, andtheendpointisdiagnosis of, ordeathfrom, a
particular disease in a previously disease-free indi-
vidual. Xo(t) may then be interpreted as the age-
specific incidence or mortality rate for a standard
covariate set, while exp (B'z) represents the relative
risk or rate ratio (RR) for a subjectwith covariates z.
These are computed from the presumed risk factors
under investigation and may themselves depend on
age. Application of the previously discussed
methodology based on the PH model is straightfor-
ward, at least in principle. A slight modification is
that the risk setsR(tk) may change with age not only
due to the loss of individuals from further observa-
tion, as inclinical trials, but also from the enrollment
of new subjects in the study at later ages.
Prospective epidemiologic studies involve a
cohort of disease-free persons who are enrolled at
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FIGURE 3. Remissionduration curves forfourgroups ofleukemic childrenaccording to theirprognostic
score, and predicted curves on basis of the PH model.
various ages andkept undercontinuous surveillance
until they eitherdevelop the disease, orelse are lost
to further observation or die from another cause. In
order to collect enough cases of rare chronic dis-
eases, tensorevenhundreds ofthousandsofpersons
may have to be followed over several years. For
example, the Radiation Effects Research Founda-
tion(RERF) haskeptnearly 100,000 survivors ofthe
Hiroshima and Nagasaki atomic bomb blasts under
surveillance for nearly three decades, losing fewer
than0.1% toemigration. With suchlarge cohorts the
previously discussed iterative methods for estima-
tionandtestingoftheparameters,8andXo areneither
feasible nor necessary.
One method of dealing with large cohorts is to
partitionthetimeorageaxisintointervals, saytenor
twenty,and topostulate adiscretetimemodelforthe
conditional probabilities offailure within each one.
Suppose there areKsuch intervals(0,tl[, (tl,t2],
(tK1, tK], and set
Pk(Z) = P[T S tkIT < tk-1, Z] (22)
for k = 1, 2, . . ., K, where T denotes the random
failure time (age at diagnosis or death), for a subject
Environmental Health Perspectives 188with covariates z. Such an individual contributes a
termpk(z) to thelikelihood ifhe develops the disease
in the k-th interval, and a term {1 - Pk(z)} if he
survives it. Ifhe dies ofother causes (is censored) in
the interval, Thompson (18) makes the sensible rec-
ommendation thathe contribute aterm 71 -Pk(Z), to
reflect his survival disease-free over only a part of
the interval.
Cox (6) suggested the use of the linear logistic
model
logitPk(Z) = ak + /3'Z (23)
where
logit(p) = In in/(l - p)} (24)
This reduces to the PH model in the limit as K in-
creases and the time or age intervals become infi-
nitely small. The term exp (,3' z) in Eq. (23) repre-
sents the odds ratio of disease occurrence in each
interval,
Pk(Z){ - Pk (O)} = exo r3, z'
{- Pk (Z)} Pk(O)
rather than the ratio of instantaneous failure rates.
A similar model was one ofseveral used by Otake
(19) to explore the effects of radiation on cause-
specific mortality using RERF data. He divided the
sample into five groups according to age at the time
of bomb (ATB) and six classes according to esti-
matedtotal radiationdoses, andconsidered avariety
ofcauses ofdeath as the endpoint. Ifnij denotes the
numberofsubjects in age group i and radiation class
j, while dij denotes the number of deaths due to
specific cause, then his model states
logitE(dijln,) = ai + 1j
subjecttoappropriate constraints ontheparameters.
This is a linear logistic model for the unconditional
probabilities of death over a defined period (in this
case 1950-1972) and so does not explicitly account
forcompetingcausesofdeathordifferentiallossesto
furtherobservation which may betakingplace inthe
30 age x dose cells.
Cox'smodelbasedontheconditionalprobabilities
would further divide the follow-up period into K
intervals, say 1950-1954, 1955-1959, etc. Ifnik then
denotesthe numberofsubjects who were ageiATB,
received radiation dosej, and who remained alive at
the midpoint of the k-th interval, the model is
logitE(diJkln/Jk) = ai +/ + Yk (27)
One might include also an interaction term (ay)ik so
as to allow age and calendar time to have essentially
arbitrary effects on disease incidence. The numbers
of deaths dijk may be formally considered to have
independent binomial distributions conditionally on
the nik (4).
A different approach to this problem, termed by
Mantel a "synthetic retrospective study," isto draw
asmall sample ofdisease-free "controls" from each
of the risk sets R(tk) for comparison with the dis-
eased cases as they arise. The very same theory and
methods may be applied also to actual case/control
studiesinwhich cases are ascertained as they occur,
for example through a population based disease re-
gister. The controls, instead ofbeingobtainedfroma
computer file, are samples from the population in
which the case arose. They may be patients with
differentdiagnosesinthe samehospital, chosenfrom
the samefamily orneighborhood, orsimply sampled
at random from the population.
While it is impossible to estimate the incidence
rates Xo(t) without studying the full cohort, the PH
model assumed for the prospective study implies a
probability structure for the sample cases and con-
trols which may be used to estimate the parameter,8
describing the RR associated with the covariates
(20). Specifically, suppose m = m(t) cases having
covariate vectors zl, ..., Zm are diagnosed (or die)
withtheparticulardisease at aget. Suppose also that
n disease-free controls with covariatesZm+i, * * * Zm+n
aredrawnatrandomfromtherisk set. Theanalysis is
performed conditionally onfixed values form, n and
the combined set ofn + m observed covariate vec-
tors. Using Cox's linearlogistic model forthe condi-
tional failure probabilities, the likelihood that m in-
dividuals with indices i1, . . ., lm are cases and the
remainder are controls, given that they all survive to
age t, is
m m+n
H exp {(a + ,l3' zi H (1 + exp {a + 3z'j})-1
i= I j= (28)
where a = a(t). Consequently theconditional proba-
bility that the first m z's correspond to cases (as
observed), and the remainder to controls, is
exp {(/3's)}
I exp (,/'sl) IfR(m,n) (29)
where I = (I1, . . ., 'm) ranges over the setR(m,n) of
(m+n) subsets ofsizem from{1, 2, . . .,m +n}, s = z
+ ...+ z, and s = zll + ... +Zlm.
IfMk cases and nk controls are sampled at age tk,
October 1979 189the conditional likelihood function for , may be
written
of the controls in the k-th set, k = 1, . . ., K. The
conditional likelihood may then be written
K
rl (exp {1'Sk}/ E exp {f3's1})
k = I IfR(mk,nk) (30)
This expression is formally identical to that given
earlier for the PH model in survival analysis. How-
ever now the risk sets R(tk), instead of containing
everyone still alive and disease-free at tk, are re-
placed by the much smaller sets ofmk + nk subjects
actually sampled for the retrospective analysis.
In practice, the sets ofm + n cases and controls
maybe matched on othervariables xbesides age, for
example on risk factors already known to be as-
sociated with the disease under investigation. The
PH model may then be generalized to
X(t|z,x) = exp {f,'z} Xo(tlx) (31)
which allows the underlying incidence function Xo to
depend in an arbitrary way on x as well as t. Interac-
tions between the matching variables and the risk
factors continue to be modelled in z. Retrospective
sampling carried outwithin risk sets having similar x
and t values leads to the same conditional likelihood
given above (20).
A special case ofthe conditional likelihood occurs
wheneach case is individually matched to exactlyR
controls, asituationfoundoften inpractice. Suppose
there areK such sets and denote by ZOk the covariate
vectorforthe case and by Zlk, ..., ZRkthe covariates
K
k =
1
R
1 + I exp {/3' (Zik - ZOk)}
j = I
(32)
This approach was taken with an RERF data file
consisting of records on 7078 males who were 50+
years old ATB. Thirteen deaths from leukemia oc-
curred (Table 8). For each of these a search was
made to determine the risk sets ofpotential controls
who had the same age ATB (exact year), were resid-
ing in the same city (Hiroshima or Nagasaki), and
who were alive at the end ofthe same year in which
the case died. These ranged in size from 30 to 508
individuals.
In order to illustrate the application of the case/
control methodology, a series of 1, 2, 5, 10, and 20
controls was drawn at random from each ofthe risk
sets. Two covariates were computed from the esti-
mated radiation dose (in rads) for each subject:
zl = ln (rads + 1) and Z2 = JiaiTs. The choice of ln
(rads + 1) as a covariate in the PH model, which
impliesthereis alinearincrease inlnRRwith In(rads
+ 1), was based on two facts: the highly skewed
distribution ofradiation doses; and Figure 2ofOtake
(19), which shows anonlinear increase in In RR with
dose after about 200 rad. The alternate transforma-
tion Vrads was used for comparison.
Results ofthe matched analyses based on the dif-
Table 8. Summary data on records used for matched case-control analysis of RERF files.
Risk set
Age Year of Dose,
Case ID City ATB death rad Size Dosela
1 252750b H 56 1957 0 303 2
2 278624b H 56 1957 14 303 1
3 090238 N 50 1967 325 73 4
4 091006 N 55 1959 163 79 2
254898 H 60 1953 0 251 4
6 257863 H 51 1953 24 508 2
7 275949 H 51 1958 238 445 2
8 400967 H 57 1954 574 345 2
9 401117 H 63 1958 867 116 1
10 434199 H 66 1956 8 99 2
11 437743 H 52 1963 38 293 3
12 468806 H 50 1960 NICC 419 2
13 083922 N 50 1976 13 30 6
aGeometric mean dose for 30 controls sampled at random from risk set.
bNote that these two cases have identical risk sets as they lived in the same city and had the same years of birth and death. cNot in city ATB (0 dose).
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Number of Coefficients RR estimate for dose
controls in
Covariate analysis ,8 S.E. 10 50 200 Ln-Lik
z = In (rads + 1) 1 0.284 0.201 1.98 3.06 4.51 -7.78
2 0.434 0.205 2.83 5.50 9.97 -11.08
5 0.482 0.163 3.18 6.66 12.91 -17.69
10 0.415 0.134 2.71 5.12 9.05 -25.88
20 0.475 0.131 3.12 6.48 12.43 -32.75
z = ds 1 0.049 0.046 1.17 1.42 2.02 -8.34
2 0.085 0.049 1.31 1.83 3.35 -12.22
5 0.117 0.044 1.45 2.28 5.20 -18.89
10 0.095 0.033 1.35 1.96 3.83 -27.18
20 0.077 0.029 1.28 1.73 2.98 -35.90
Table 10. Comparison of matched and unmatched analyses of RERF files: twenty controls per case.
Regression coefficients ± S.E. RR estimate for dose
Covariate Const z Z2 10 50 200
z = In (rads + 1) Matched 0.475 ± 0.131 3.12 6.48 12.43
Unmatched -3.971 ± 0.484 0.453 ± 0.123 2.96 5.93 11.04
Unmatched -4.105 ± 0.583 0.626 ± 0.386 - 0.027 ± 0.056 3.85 7.77 13.08
Test for quadratic effect: x2, = 0.23
z = rads Matched 0.077 ± 0.029 1.28 .73 2.98
Unmatched -3.332 ± 0.337 0.072 ± 0.027 - 1.18 1.67 2.77
Unmatched -3.877 ± 0.470 0.255 + 0.100 -0.005 ± 0.004 2.20 4.71 13.33
Test for quadratic effect Xi = 7.34
ferent numbers of controls are shown in Table 9.
Notethedecreaseintheestimated standard errors as
additional controls are used; however the gain af-
fordedbyusingtwenty ratherthan tencontrols is not
great. The regression coefficients of 0.4-0.5 for ln
(rads + 1) indicatethat, roughly speaking, the riskof
leukemia increases by about 5% for every 10% in-
crease in radiation dose.
The disparity between the relative risks fitted
underthe modelz = ln (rads + 1) vs. those fitted by
z = rads is quite noticeable, especially when one
recalls that most doses fall in the 0 - 200 range. In
order to try to understand better why this might
occur, unmatched logistic regression analyses were
carriedoutonthe dataconsisting ofall cases and the
sets of twenty controls. The estimated slopes and
standard errors were similar to those obtained with
the matched analysis (Table 10). However the inter-
cepts, corresponding to the estimated log odds of
leukemia in the sample at a dose of zero rads, dif-
fered markedly between the two models: a = -3.97
for z = ln (rads + 1) vs. a = -3.33 for z = 7rads.
Differences in the estimated relative risk between
the two models were thus explained largely by the
differences in the absolute risks estimated for the
baseline value of the covariate.
A potential hazard of the regression modelling of
relativerisksisitssensitivity to thechoiceofscaleon
which the covariate is measured. Goodness offit of
the model to the data is essential for proper in-
terpretation, and should be explored thoroughly.
Whenbothlinearandquadraticcovariate termswere
fitted with the models above, for example, the
agreement between the estimated values for a im-
proved substantially. Moreover the fact that the
quadratic term was highly significant for the /ads
model, and not at all significant for the In (rads + 1)
model, showed that the latter gave much betterfit to
these data (Table 10).
Further Reading
Muchofthe above material is presented in greater
detail in areview article (10) on the PH model and its
applications to survival data. Some additional appli-
cations of this model to epidemiologic studies are
given by Breslow et al. (21, 22). Peto et al. (23)
October 1979 191present athorough discussion ofits use in the design
and analysis of clinical trials.
A computer program for calculating the PL esti-
mate and all the test statistics presented in sections
2-5 above is available (24).
Several authors havepointedoutthatthe W scores
defined do not lead to the most efficient generaliza-
tion of Wilcoxon's test to censored data. They all
propose essentially the same statistic as an alternate
generalization (7, 25, 26).
A comparison ofthe efficiencies ofthe test statis-
tics using Monte Carlo techniques is made by Lee et
al. (27). Efron (17) discusses the efficiency of the
likelihood function used with the PH model from a
more abstract viewpoint; see also Kalbfleisch (28).
Additional extensions ofthe PH regression model
for use with grouped or heavily tied data are dis-
cussed by Cox (6), Kalbfleisch and Prentice (15),
Thompson (18), and Prentice and Gloeckler (29).
This work was supported in part by Grant CA-11722 from the
U.S. National Institutes of Health.
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